BR112021024592A2 - Sequência líder - Google Patents
Sequência líderInfo
- Publication number
- BR112021024592A2 BR112021024592A2 BR112021024592A BR112021024592A BR112021024592A2 BR 112021024592 A2 BR112021024592 A2 BR 112021024592A2 BR 112021024592 A BR112021024592 A BR 112021024592A BR 112021024592 A BR112021024592 A BR 112021024592A BR 112021024592 A2 BR112021024592 A2 BR 112021024592A2
- Authority
- BR
- Brazil
- Prior art keywords
- leader sequence
- pvc
- payload
- effector
- needle complex
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1908155.3A GB201908155D0 (en) | 2019-06-07 | 2019-06-07 | Leader sequence |
| PCT/GB2020/051380 WO2020245611A1 (en) | 2019-06-07 | 2020-06-05 | Leader sequence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021024592A2 true BR112021024592A2 (pt) | 2022-01-18 |
Family
ID=67386182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021024592A BR112021024592A2 (pt) | 2019-06-07 | 2020-06-05 | Sequência líder |
Country Status (12)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116554283A (zh) * | 2022-01-29 | 2023-08-08 | 中国医学科学院病原生物学研究所 | 多肽注射系统及其用途 |
| EP4479082A4 (en) | 2022-02-15 | 2026-06-10 | Broad Inst Inc | CELL-TYPE SPECIFIC TARGETING CONTRACTILE INJECTION SYSTEM |
| EP4547848A1 (en) | 2022-06-30 | 2025-05-07 | Københavns Universitet | Contractile injection system and use thereof |
| CN119735656A (zh) * | 2023-09-22 | 2025-04-01 | 北京朝赛蕴生物科技有限公司 | 一种蛋白复合物的制备纯化及应用 |
| GB202417349D0 (en) | 2024-11-26 | 2025-01-08 | Nanosyrinx Ltd | Method of purification |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| US9951340B2 (en) * | 2013-03-07 | 2018-04-24 | The General Hospital Corporation | Compositions and methods for bacterial delivery of polypeptides |
| RU2755282C2 (ru) * | 2015-10-14 | 2021-09-14 | Байер Кропсайенс Лп | Ген ахм1554, кодирующий дельта-эндотоксин, и способы его применения |
-
2019
- 2019-06-07 GB GBGB1908155.3A patent/GB201908155D0/en not_active Ceased
-
2020
- 2020-06-05 JP JP2021572387A patent/JP7748288B2/ja active Active
- 2020-06-05 EP EP20732657.0A patent/EP3980545A1/en active Pending
- 2020-06-05 SG SG11202113297RA patent/SG11202113297RA/en unknown
- 2020-06-05 KR KR1020217042571A patent/KR20220133757A/ko not_active Ceased
- 2020-06-05 WO PCT/GB2020/051380 patent/WO2020245611A1/en not_active Ceased
- 2020-06-05 US US17/613,911 patent/US20230076614A1/en active Pending
- 2020-06-05 MX MX2021015121A patent/MX2021015121A/es unknown
- 2020-06-05 CA CA3142462A patent/CA3142462A1/en active Pending
- 2020-06-05 CN CN202080042046.3A patent/CN114008205A/zh active Pending
- 2020-06-05 BR BR112021024592A patent/BR112021024592A2/pt unknown
- 2020-06-05 AU AU2020288380A patent/AU2020288380B2/en active Active
-
2025
- 2025-04-10 JP JP2025064761A patent/JP7866663B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3142462A1 (en) | 2020-12-10 |
| SG11202113297RA (en) | 2021-12-30 |
| JP7866663B2 (ja) | 2026-05-27 |
| AU2020288380B2 (en) | 2026-07-09 |
| US20230076614A1 (en) | 2023-03-09 |
| EP3980545A1 (en) | 2022-04-13 |
| WO2020245611A1 (en) | 2020-12-10 |
| MX2021015121A (es) | 2022-03-17 |
| KR20220133757A (ko) | 2022-10-05 |
| JP7748288B2 (ja) | 2025-10-02 |
| CN114008205A (zh) | 2022-02-01 |
| JP2025114573A (ja) | 2025-08-05 |
| GB201908155D0 (en) | 2019-07-24 |
| JP2022535283A (ja) | 2022-08-05 |
| AU2020288380A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021015121A (es) | Secuencias lider. | |
| BR112021022879A2 (pt) | Sistemas e métodos para avaliação de fração tumoral | |
| BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| CO2019003809A2 (es) | Anticuerpos contra proteína alfa reguladora de señal y métodos de uso | |
| CR20200392A (es) | Anticuerpos anti-cd73 y métodos de uso de los mismos | |
| BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
| BR112023005674A2 (pt) | Construtos anti-cd93 e usos dos mesmos | |
| BR112018002848A2 (pt) | método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular | |
| BR112017003194A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra. | |
| BR112017025564B8 (pt) | Anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
| BR122020006914B8 (pt) | Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| BR112018000768A2 (pt) | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos | |
| BR112017012944A2 (pt) | ?anticorpo, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e, método para prevenção, tratamento ou melhoria de pelo menos um sintoma de infecção de influenza? | |
| BR112018073674A2 (pt) | polipeptídeo glicosilado, proteína glicosilada, uso de um polipeptídeo glicosilado, composição, polinucleotídeo isolado, vetor, e célula hospedeira | |
| MX2016014813A (es) | Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos. | |
| CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| BR112013008407A2 (pt) | antígenos de clostridium difficile | |
| BR112017026523A2 (pt) | vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado. | |
| BR112017001463A2 (pt) | célula hospedeira melhorada para produzir proteínas | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| BR112016016737A2 (pt) | Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma | |
| BR112019000742A2 (pt) | método e kit para analisar uma amostra | |
| BR112016014010A2 (pt) | métodos para detectar anticorpos contra vírus da febre suína clássica tipo selvagem (csfv), para diferenciação entre animais infectados com csfv tipo selvagem e animais que foram vacinados contra csfv e para controlar uma infecção com csfv tipo selvagem, kit de teste de diagnóstico, e, uso de um carreador |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: NANOSYRINX LIMITED (GB) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |